Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Go back to Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 35.10 +0.94 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.16 | 52 Week High | $71.49 | |||
| Open | $34.30 | 52 Week Low | $33.50 | |||
| Day High | $35.53 | P/E | N/A | |||
| Day Low | $34.30 | EPS | $-1.18 | |||
| Volume | 1,378,824 | |||||
